Brainsway and Evolus are both small-cap medical companies with distinct business models and market positions. Brainsway develops noninvasive neurostimulation treatments for mental health disorders, while Evolus operates in the aesthetic beauty market. A financial comparison reveals different strengths across key investment metrics.
Risk and Volatility
Brainsway has a beta of 1.23, meaning its share price is 23% more volatile than the S&P 500. Evolus carries higher volatility with a beta of 1.28, indicating its share price is 28% more volatile than the S&P 500.
Analyst Outlook
Brainsway currently has a consensus price target of $15.00, indicating potential upside of 0.74%. Evolus has a consensus price target of $16.00, indicating potential upside of 149.03%. According to the comparison, analysts believe Evolus is more favorable than Brainsway based on its higher probable upside.
Institutional and Insider Ownership
Brainsway and Evolus differ significantly in their ownership structures. Institutional investors hold 30.1% of Brainsway shares compared to 90.7% of Evolus shares. Conversely, insiders hold 19.0% of Brainsway shares versus 5.0% of Evolus shares. Strong institutional ownership is described as an indication that endowments, hedge funds, and large money managers believe a company is positioned for long-term growth.
Company Profiles
BrainsWay Ltd., founded in 2003 and headquartered in Jerusalem, Israel, offers Deep Transcranial Magnetic Stimulation platform technology for treating major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in psychiatry.
Evolus, Inc., incorporated in 2012 and headquartered in Newport Beach, California, focuses on the cash-pay aesthetic market across the United States, Canada, and Europe. The company offers Jeuveau, described as a proprietary 900 kilodalton purified botulinum toxin type A formulation for temporary improvement in moderate to severe glabellar lines in adults, along with dermal filler products under the Estyme and Evolysse names.
Across 14 factors compared, Brainsway beats Evolus on 9 of them, though the analysis does not detail which specific metrics favor each company.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.thelincolnianonline.com/2026/05/19/financial-comparison-brainsway-nasdaqbway-and-evolus-nasdaqeols.html